TuisGMAB • CPH
add
Genmab
Vorige sluiting
kr 1 394,00
Dagwisseling
kr 1 398,50 - kr 1 417,00
Jaarwisseling
kr 1 398,50 - kr 2 171,00
Markkapitalisasie
92,26 mjd DKK
Gemiddelde volume
112,60 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
CPH
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (DKK) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 5,54 mjd | 17,57% |
Bedryfskoste | 3,15 mjd | 6,78% |
Netto inkomste | 1,27 mjd | -39,83% |
Netto winsgrens | 22,85 | -48,82% |
Wins per aandeel | 0,29 | -38,43% |
EBITDA | 2,20 mjd | 26,09% |
Effektiewe belastingkoers | 26,35% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (DKK) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 17,32 mjd | -37,08% |
Totale bates | 39,66 mjd | 12,55% |
Totale aanspreeklikheid | 7,74 mjd | 87,54% |
Totale ekwiteit | 31,92 mjd | — |
Uitstaande aandele | 63,51 m | — |
Prys om te bespreek | 2,77 | — |
Opbrengs op bates | 13,53% | — |
Opbrengs op kapitaal | 16,33% | — |
Kontantvloei
Netto kontantverandering
| (DKK) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,27 mjd | -39,83% |
Kontant van bedrywe | 2,03 mjd | -0,20% |
Kontant van beleggings | 224,00 m | -77,78% |
Kontant van finansiering | -276,00 m | -1 480,00% |
Netto kontantverandering | 2,01 mjd | -40,84% |
Beskikbare kontantvloei | 1,42 mjd | 9,09% |
Meer oor
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. Wikipedia
Gestig
1999
Webwerf
Werknemers
2 635
